Skip to Main ContentSkip to FooterSkip to Search
  1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Cell Therapy
  6.  » An Interview: Spotlight on iPSCs

An Interview: Spotlight on iPSCs

Summary:​ Catalent and RegMedNet showcase how induced pluripotent stem cells can catalyze the advancement of novel cell therapies. This feature explores biological, clinical and commercial characteristics of iPSCs as ideal starting materials.

Learn how iPSCs – especially HLA-homozyogous cell lines – constitute a universal “off-the-shelf” source of materials for a spectrum of cell therapies. 

Advancing towards a universal platform for iPSC-based therapies: an interview with Boris Greber and Thomas Marx

Click here to view the Article